From: Impact of the COVID-19 pandemic on cerebral venous sinus thrombosis in China: a comparative study
Risk Factor | Unadjusted OR (95% CI) | P value | Adjusted OR (95% CI) | P value |
---|---|---|---|---|
CNS infection | 6.013 (1.390–26.011) | 0.016 | 0.615 (0.099–3.823) | 0.602 |
Obstetric causes | 1.116 (0.553–2.253) | 0.759 | - | - |
Oral contraceptives, HRT | 1.995 (1.043–3.819) | 0.037 | 3.000 (0.556–16.186) | 0.201 |
Hematologic disorders | 1.947 (1.115–3.397) | 0.019 | 1.778 (0.411–7.697) | 0.442 |
Anemia | 2.232 (1.213–4.107) | 0.010 | 6.000 (1.445–24.919) | 0.014 |
Polycythemia | 4.426 (0.725–27.028) | 0.107 | 2.889 (0.325–25.702) | 0.341 |
Transfusion | 1.639 (0.340–7.901) | 0.538 | - | - |
Prothrombotic conditions | 1.901 (1.093–3.304) | 0.023 | 1.821 (0.885–3.747) | 0.104 |
PS reduction | 1.604 (0.934–2.754) | 0.087 | 0.482 (0.129–1.795) | 0.277 |
AT reduction | 1.429 (0.567–3.601) | 0.450 | - | - |
Hyperhomocysteinemia | 1.479 (0.742–2.946) | 0.266 | - | - |
Antiphospholipid and anticardiolipin antibodies | 1.119 (0.479–2.616) | 0.795 | - | - |
Any malignancies | 1.454 (0.307–6.887) | 0.637 | - | - |